Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
IgE signaling through its high-affinity receptor FcεRI is central to the pathogenesis of numerous allergic disorders. Oral inhibitors of Bruton's tyrosine kinase (BTKis), which are currently FDA-approved for the treatment of B cell malignancies, broadly inhibit the FcεRI pathway in human mast c...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Revisão |
| 言語: | 英語 |
| 出版事項: |
2024
|
| オンライン･アクセス: | https://doi.org/10.1016/j.anai.2024.03.002 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|